Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2004

View Archived Issues

Glufast launched in Japan

Prostaglandins suggested as a potential target in ulcerative colitis

Alvimopan improves gastrointestinal transit in POI and chronic constipation

Immunological changes induced by glatiramer acetate in an experimental colitis model

FK-778 results presented at American transplantation congress

Levetiracetam: advantageous treatment for seizures after liver transplantation

ISA-247 more potent than ciclosporin in renal transplant recipients

Valganciclovir simple, effective as CMV prophylaxis in renal transplantation

Alemtuzumab use may reduce tacrolimus toxicity in liver transplantation

Enrollment completed in phase III trial of enoximone

ProMetic achieves second milestone in AM-Pharma agreement

Biomira and Inno-centre Alberta to create spin-off company to develop L-IL-2 technology

Favrille receives SPA from FDA for FavID

FDA approves Taxotere for treatment of prostate cancer

MorphoSys and Novartis to discover and develop antibody-based therapeutic agents

Avelox approved for treatment of CAP caused by multidrug resistant S. pneumoniae

Zimycan receives approval in Belgium for treatment of diaper dermatitis

Phase 2 Discovery receives positive results from phase II trial with PD-6735

Enzo Biochem to begin phase I trial of EGS-21

Positive data reported from phase IIIb Xyrem study

Duloxetine may be safe and effective for diabetic neuropathic pain

Ziconotide could be safe and effective in malignant and nonmalignant pain

Enrollment commences in phase III Altropane trial

CRADA to develop stem cell technology for cardiovascular disease treatment

Onco TCS NDA accepted for review

inGenium aids Peregrine's development of monoclonal antibody for lymphoma

Yamanouchi presents activators of PGC-1 and mtTFA genes and their therapeutic use

New antidepressant agents with 5-HT reuptake, H1 and 5-HT2 blocking activity

Novel PDE4 inhibitors and their use covered by Takeda patent

Gruenenthal scientists design novel NOS inhibitors

New interferon inducers for topical application designed at Sumitomo

New stilbene-based immunomodulators prepared and tested at Welichem

New neurotrophic agents and their use in Parkinson's disease, ALS, stroke, etc.

Activity of LBM-415 extensively investigated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...